Replies to post #5027 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

U.S. ATryn Development Timeline for HD Indication

[Based on the guidance from the BIO webcast this week.]

4Q07: Complete study; report top-line results; begin “rolling” BLA submission.

1Q08: Report antibody data; complete data analysis.

Mid 2008: Submit final module of BLA.

Late 2008/early 2009: FDA decision on BLA (assuming a six-month priority review).